Navigation Links
Leukemia Patients Taking Gleevec Achieve 'Normal' Death Rate

TUESDAY, March 22 (HealthDay News) -- The death rate of patients with chronic myeloid leukemia who took Gleevec and were in remission two years after treatment was similar to the death rate in the general population, a new study shows.

Italian researchers collected data on 832 patients who were taking Gleevec (imatinib) for up to eight years and found that 20 patients died during the follow-up period. That death rate of 4.8 percent, however, is similar to what would be expected in the general population.

Only six deaths were related to chronic myeloid leukemia (CML), the researchers noted.

Serious adverse events such as cardiovascular and digestive problems were reported in 139 patents, but only 27 cases (19 percent) were considered to be related to Gleevec, according to the study.

Other adverse events frequently connected to Gleevec included muscle cramps, weakness, edema, skin fragility, diarrhea, and tendon or ligament lesions. Nineteen patients (2.3 percent) stopped taking Gleevec due to side effects, with half switching to another drug.

Patients taking Gleevec "frequently suffer from side effects that are non-serious but can nonetheless reduce their quality of life," the researchers wrote.

The study authors disclosed no conflicts of interest, noting that their independence from pharmaceutical interests was a major strength of the study.

The researchers also noted the "importance of a good patient-provider relationship, in which side effects are easily communicated and addressed to reduce/avoid non-compliance."

In an accompanying editorial, Dr. B. Douglas Smith of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, noted "the astounding effect [imatinib] has had on the clinical course of this disease."

However, he wrote that many patients in the study had been treated first with interferon, which may have been a factor in their remissions. For this reason, he concluded, "a careful analysis of the two groups" -- patients who had taken interferon and those who had not -- "might help shed light on this issue."

The study appears online March 22 in the Journal of the National Cancer Institute.

More information

The American Cancer Society has more about chronic myeloid leukemia.

-- Robert Preidt

SOURCE: Journal of the National Cancer Institute, March 22, 2011

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Less Is More With Acute Myeloid Leukemia Drug
2. When leukemia returns, gene that mediates response to key drug often mutated
3. A small subset of normal white blood cells gives rise to a rare leukemia, study shows
4. Scientists bioengineer a protein to fight leukemia
5. Southampton scientists begin patient trials of new leukemia cancer vaccine
6. Discovery of a gene associated with a leukemia mostly affecting children
7. MicroRNA-TP53 circuit connected to chronic lymphocytic leukemia
8. Gene Activity May Affect Acute Myeloid Leukemia Outcome
9. Intensive chemotherapy can dramatically boost survival of older teenage leukemia patients
10. Researchers make critical leukemia stem cell discovery
11. New therapies and gene target advance the treatment and understanding of hard-to-treat leukemias
Post Your Comments:
Related Image:
Leukemia Patients Taking Gleevec Achieve 'Normal' Death Rate
(Date:11/25/2015)... ... November 25, 2015 , ... Finnleo, a leader in the traditional ... models of traditional and far-infrared saunas. , For traditional saunas, Finnleo is ... traditional Finnish sauna wood, and Finnleo uses only European Grade A Nordic White Spruce ...
(Date:11/25/2015)... ... 26, 2015 , ... Ministers, senior government and UN agencies, ... Centres of Excellence, and public R&D institutions, civil societies and other partners gathered ... 5th African Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders Meeting. The three- ...
(Date:11/25/2015)... ... November 25, 2015 , ... Lakeview Health, a Jacksonville-based drug ... their sobriety and show through pictures what a positive difference it makes. The ... with the hashtag #FacesOfGratitude on their Facebook, Twitter, and Instagram accounts. Short ...
(Date:11/25/2015)... ... November 25, 2015 , ... The McHenry County law firm of ... decision obtained by Attorneys Francisco J. Botto and Alex C. Wimmer. Attorneys Botto and ... Comm’n, 2015 IL App (2d) 130884WC. , According to court documents, Adcock testified that ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Beddit® has ... Beddit Classic sleep tracking systems. The new app features a more intuitive SleepScore™ that ... understand how well you slept. The SleepScore is created by a proprietary algorithm. Beddit ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 25, 2015 Allergan plc (NYSE: ... Rugen Therapeutics, a start-up  biotechnology company focused on ... disorders and funded by the F-Prime Biomedical Research ... into an exclusive collaboration to support the discovery ... Disorders (ASD) and Obsessive Compulsive disorders (OCD). ...
(Date:11/25/2015)... 2015 USP 800 applies to all ... pharmacists, pharmacy technicians, nurses, physicians, physician assistants, home ... also covers all entities which store, prepare, transport, ... healthcare institutions, patient treatment clinics, physicians, practice facilities, ... --> What is the purpose of ...
(Date:11/25/2015)... 2015 Asia -based ... BioLight and the New Investors will make a direct ... a private placement. The financing will help IOPtima to ... used in the treatment of glaucoma, as well as ... IOPtimate™ system with the U.S. Food and Drug Administration, ...
Breaking Medicine Technology: